Definition
Cholesterol is indispensable for tissues and cells of human beings. It is not only an important substance participating in the formation of cell membranes but also a kind of material for the synthesis of bile acids, vitamin D, and steroid hormones. A human being can get cholesterol from routine diet. But the main source of cholesterol is synthesized by the liver. Cholesterol is transported through the blood by the apolipoprotein to vessels, adrenal gland, ovary, and other oranges or tissues. However, excessive cholesterol can be deposited in the vascular wall, leading to a variety of cardiovascular diseases. LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C) are two main components of plasma cholesterol. High total cholesterol and high LDL-C levels are widely regarded as casual predicted factors for cardiovascular events. However, the relevance of HDL-C level to...
This is a preview of subscription content, log in via an institution to check access.
References
Abbott RD, Garrison RJ, Wilson PW et al (1983) Joint distribution of lipoprotein cholesterol classes. The Framingham study. Arteriosclerosis 3(3):260–272. https://doi.org/10.1161/01.ATV.3.3.260
Almansob MA, Xu B, Zhou L et al (2012) Simvastatin reduces myocardial injury undergoing noncoronary artery cardiac surgery: a randomized controlled trial. Arterioscler Thromb Vasc Biol 32(9):2304–2313. https://doi.org/10.1161/atvbaha.112.252098
Baigent C, Landray MJ, Reith C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet 377(9784):2181–2192. https://doi.org/10.1016/s0140-6736(11)60739-3
Blazek A, Rutsky J, Osei K et al (2013) Exercise-mediated changes in high-density lipoprotein: impact on form and function. Am Heart J 166(3):392–400. https://doi.org/10.1016/j.ahj.2013.05.021
Cannon CP, Blazing MA, Giugliano RP et al (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372(25):2387–2397. https://doi.org/10.1056/NEJMoa1410489
Castelli WP, Garrison RJ, Wilson PW et al (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. JAMA 256(20):2835–2838. https://doi.org/10.1001/jama.1986.03380200073024
Chang FJ, Yuan HY, Hu XX et al (2014) High density lipoprotein from patients with valvular heart disease uncouples endothelial nitric oxide synthase. J Mol Cell Cardiol 74:209–219. https://doi.org/10.1016/j.yjmcc.2014.05.015
Cho KH, Park HJ, Kim JR (2020) Decrease in serum HDL-C level is associated with elevation of blood pressure: correlation analysis from the Korean National Health and nutrition examination survey 2017. Int J Environ Res Public Health 17(3). https://doi.org/10.3390/ijerph17031101
Dayimu A, Wang C, Li J et al (2019) Trajectories of lipids profile and incident cardiovascular disease risk: a longitudinal cohort study. J Am Heart Assoc 8(21):e013479. https://doi.org/10.1161/jaha.119.013479
Ference BA, Ginsberg HN, Graham I et al (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J 38(32):2459–2472. https://doi.org/10.1093/eurheartj/ehx144
Grundy SM, D’Agostino RB Sr, Mosca L et al (2001) Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, lung, and blood institute workshop. Circulation 104(4):491–496. https://doi.org/10.1161/01.CIR.104.4.491
Guo Y, Zhao M, Bo T et al (2019) Blocking FSH inhibits hepatic cholesterol biosynthesis and reduces serum cholesterol. Cell Res 29:151–166. https://doi.org/10.1038/s41422-018-0123-6
Hirowatari Y, Homma Y, Yoshizawa J et al (2012) Increase of electronegative-LDL-fraction ratio and IDL-cholesterol in chronic kidney disease patients with hemodialysis treatment. Lipids Health Dis 11:111. https://doi.org/10.1186/1476-511x-11-111
Holmes MV, Millwood IY, Kartsonaki C et al (2018) Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke. J Am Coll Cardiol 71(6):620–632. https://doi.org/10.1016/j.jacc.2017.12.006
Igarashi Y, Nogami Y (2019) Response of lipids and lipoproteins to regular aquatic endurance exercise: a meta-analysis of randomized controlled trials. J Atheroscler Thromb 26(1):14–30. https://doi.org/10.5551/jat.42937
Ishigaki Y, Kawagishi N, Hasegawa Y et al (2019) Liver transplantation for homozygous familial hypercholesterolemia. J Atheroscler Thromb 26:121–127. https://doi.org/10.5551/jat.RV17029
Jun M, Foote C, Lv J et al (2010) Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375(9729):1875–1884. https://doi.org/10.1016/s0140-6736(10)60656-3
Kawakami A, Aikawa M, Alcaide P et al (2006a) Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 114(7):681–687. https://doi.org/10.1161/circulationaha.106.622514
Kawakami A, Aikawa M, Libby P et al (2006b) Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 113(5):691–700. https://doi.org/10.1161/circulationaha.105.591743
Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 380(9859):2095–2128. https://doi.org/10.1016/s0140-6736(12)61728-0
Mc Auley MT, Mooney KM (2014) Lipid metabolism and hormonal interactions: impact on cardiovascular disease and healthy aging. Expert Rev Endocrinol Metab 9(4):357–367. https://doi.org/10.1586/17446651.2014.921569
Mc Auley MT, Wilkinson DJ, Jones JJ et al (2012) A whole-body mathematical model of cholesterol metabolism and its age-associated dysregulation. BMC Syst Biol 6:130. https://doi.org/10.1186/1752-0509-6-130
Mihaylova B, Emberson J, Blackwell L et al (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380(9841):581–590. https://doi.org/10.1016/s0140-6736(12)60367-5
Millar JS, Lichtenstein AH, Cuchel M et al (1995) Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men. J Lipid Res 36(6):1155–1167
Navab M, Anantharamaiah GM, Hama S et al (2002) Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105(3):290–292. https://doi.org/10.1161/hc0302.103711
Navarese EP, Robinson JG, Kowalewski M et al (2018) Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 319(15):1566–1579. https://doi.org/10.1001/jama.2018.2525
Nofer JR, Kehrel B, Fobker M et al (2002) HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161(1):1–16. https://doi.org/10.1016/S0021-9150(01)00651-7
Norata GD, Callegari E, Marchesi M et al (2005) High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation 111(21):2805–2811. https://doi.org/10.1161/circulationaha.104.472886
Ohashi R, Mu H, Wang X et al (2005) Reverse cholesterol transport and cholesterol efflux in atherosclerosis. QJM 98(12):845–856. https://doi.org/10.1093/qjmed/hci136
Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ et al (2012) Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 51(4):314–324. https://doi.org/10.1016/j.plipres.2012.03.003
Ou J, Wang J, Xu H et al (2005) Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ Res 97(11):1190–1197. https://doi.org/10.1161/01.RES.0000190634.60042.cb
Pechlaner R, Tsimikas S, Yin X et al (2017) Very-low-density lipoprotein-associated Apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III. J Am Coll Cardiol 69(7):789–800. https://doi.org/10.1016/j.jacc.2016.11.065
Ross S, D’Mello M, Anand SS et al (2015) Effect of bile acid Sequestrants on the risk of cardiovascular events: a Mendelian randomization analysis. Circ Cardiovasc Genet 8(4):618–627. https://doi.org/10.1161/circgenetics.114.000952
Rubin EM, Krauss RM, Spangler EA et al (1991) Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353(6341):265–267. https://doi.org/10.1038/353265a0
Sacks FM, Alaupovic P, Moye LA et al (2000) VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation 102(16):1886–1892. https://doi.org/10.1161/01.CIR.102.16.1886
Schwartz GG, Olsson AG, Abt M et al (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367(22):2089–2099. https://doi.org/10.1056/NEJMoa1206797
Sharma S, Umar S, Potus F et al (2014) Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p. Circulation 130(9):776–785. https://doi.org/10.1161/circulationaha.114.007405
Soria-Florido MT, Castaner O, Lassale C et al (2020) Dysfunctional high-density lipoproteins are associated with a greater incidence of acute coronary syndrome in a population at high cardiovascular risk: a nested case-control study. Circulation 141(6):444–453. https://doi.org/10.1161/circulationaha.119.041658
Spolitu S, Okamoto H, Dai W et al (2019) Hepatic glucagon signaling regulates PCSK9 and low-density lipoprotein cholesterol. Circ Res 124(1):38–51. https://doi.org/10.1161/circresaha.118.313648
Taylor HS, Giudice LC, Lessey BA et al (2017) Treatment of endometriosis-associated pain with Elagolix, an oral GnRH antagonist. N Engl J Med 377(1):28–40. https://doi.org/10.1056/NEJMoa1700089
van Beresteijn EC, Korevaar JC, Huijbregts PC et al (1993) Perimenopausal increase in serum cholesterol: a 10-year longitudinal study. Am J Epidemiol 137(4):383–392. https://doi.org/10.1093/oxfordjournals.aje.a116686
van Vlijmen BJ, Herz J (1999) Gene targets and approaches for raising HDL. Circulation 99(1):12–14. https://doi.org/10.1161/01.CIR.99.1.12
Veniant MM, Zlot CH, Walzem RL et al (1998) Lipoprotein clearance mechanisms in LDL receptor-deficient “Apo-B48-only” and “Apo-B100-only” mice. J Clin Invest 102(8):1559–1568. https://doi.org/10.1172/jci4164
Wadhera RK, Steen DL, Khan I et al (2016) A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol 10(3):472–489. https://doi.org/10.1016/j.jacl.2015.11.010
Wang N, Tall AR (2003) Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23(7):1178–1184. https://doi.org/10.1161/01.Atv.0000075912.83860.26
Wierzbicki AS (2009) Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Curr Opin Cardiol 24(4):372–379. https://doi.org/10.1097/HCO.0b013e32832c0b3d
Wilson PW, Anderson KM, Harris T et al (1994) Determinants of change in total cholesterol and HDL-C with age: the Framingham study. J Gerontol 49(6):M252–M257. https://doi.org/10.1093/geronj/49.6.M252
Zambon A, Zhao XQ, Brown BG et al (2014) Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. Am J Cardiol 113(9):1494–1498. https://doi.org/10.1016/j.amjcard.2014.01.426
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Ou, ZJ., Mo, ZW., Ou, JS. (2020). Cholesterol Levels. In: Gu, D., Dupre, M. (eds) Encyclopedia of Gerontology and Population Aging. Springer, Cham. https://doi.org/10.1007/978-3-319-69892-2_1055-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-69892-2_1055-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-69892-2
Online ISBN: 978-3-319-69892-2
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences